WallStreetZenWallStreetZen

NASDAQ: CCCC
C4 Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CCCC past revenue growth

How has CCCC's revenue growth performed historically?
Company
-33.25%
Industry
151.46%
Market
17.61%
CCCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CCCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CCCC's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CCCC earnings and revenue history

Current Revenue
$20.8M
Current Earnings
-$132.5M
Current Profit Margin
-638.3%

CCCC Return on Equity

Current Company
-55.3%
Current Industry
-63.5%
Current Market
188%
CCCC's Return on Equity (-55.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CCCC announces earnings.

CCCC Return on Assets

Current Company
-35.8%
Current Industry
2.9%
CCCC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CCCC Return on Capital Employed

Current Company
-38.91%
Current Industry
19.5%
CCCC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CCCC vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CCCC$20.76M-$121.80M-$132.49M+1.40%N/A
AVBP$0.00-$69.33M-$69.33MN/AN/A
SLRN$0.00-$381.37M-$381.64MN/AN/A
STTK$1.66M-$82.89M-$87.30M-40.62%N/A
THRD$0.00-$30.23M-$30.82MN/AN/A
View Top Biotech Stocks

CCCC earnings dates

Next earnings date
May 2, 2024

C4 Therapeutics Earnings & Revenue FAQ

What were CCCC's earnings last quarter?

On Invalid Date, C4 Therapeutics (NASDAQ: CCCC) reported Q4 2023 earnings per share (EPS) of -$0.68, up 10.53% year over year. Total C4 Therapeutics earnings for the quarter were -$34.75 million. In the same quarter last year, C4 Therapeutics's earnings per share (EPS) was -$0.76.

If you're new to stock investing, here's how to buy C4 Therapeutics stock.

What was CCCC's earnings growth in the past year?

As of Q2 2024, C4 Therapeutics's earnings has grown year over year. C4 Therapeutics's earnings in the past year totalled -$132.49 million.

What is CCCC's earnings date?

C4 Therapeutics's earnings date is Invalid Date. Add CCCC to your watchlist to be reminded of CCCC's next earnings announcement.

What was CCCC's revenue last quarter?

On Invalid Date, C4 Therapeutics (NASDAQ: CCCC) reported Q4 2023 revenue of $3.26 million up 14.26% year over year. In the same quarter last year, C4 Therapeutics's revenue was $2.85 million.

What was CCCC's revenue growth in the past year?

As of Q2 2024, C4 Therapeutics's revenue has grown -33.25% year over year. This is 184.71 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. C4 Therapeutics's revenue in the past year totalled $20.76 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.